Literature DB >> 18079277

State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine.

Ging Kuo Wang1, Joanna Calderon, Sho-Ya Wang.   

Abstract

Ranolazine is an antianginal agent that targets a number of ion channels in the heart, including cardiac voltage-gated Na(+) channels. However, ranolazine block of muscle and neuronal Na(+) channel isoforms has not been examined. We compared the state- and use-dependent ranolazine block of Na(+) currents carried by muscle Nav1.4, cardiac Nav1.5, and neuronal Nav1.7 isoforms expressed in human embryonic kidney 293T cells. Resting and inactivated block of Na(+) channels by ranolazine were generally weak, with a 50% inhibitory concentration (IC(50)) >/= 60 microM. Use-dependent block of Na(+) channel isoforms by ranolazine during repetitive pulses (+50 mV/10 ms at 5 Hz) was strong at 100 microM, up to 77% peak current reduction for Nav1.4, 67% for Nav1.5, and 83% for Nav1.7. In addition, we found conspicuous time-dependent block of inactivation-deficient Nav1.4, Nav1.5, and Nav1.7 Na(+) currents by ranolazine with estimated IC(50) values of 2.4, 6.2, and 1.7 microM, respectively. On- and off-rates of ranolazine were 8.2 microM(-1) s(-1) and 22 s(-1), respectively, for Nav1.4 open channels and 7.1 microM(-1) s(-1) and 14 s(-1), respectively, for Nav1.7 counterparts. A F1579K mutation at the local anesthetic receptor of inactivation-deficient Nav1.4 Na(+) channels reduced the potency of ranolazine approximately 17-fold. We conclude that: 1) both muscle and neuronal Na(+) channels are as sensitive to ranolazine block as their cardiac counterparts; 2) at its therapeutic plasma concentrations, ranolazine interacts predominantly with the open but not resting or inactivated Na(+) channels; and 3) ranolazine block of open Na(+) channels is via the conserved local anesthetic receptor albeit with a relatively slow on-rate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18079277      PMCID: PMC2275669          DOI: 10.1124/mol.107.041541

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  29 in total

Review 1.  Voltage-gated sodium channels and pain pathways.

Authors:  John N Wood; James P Boorman; Kenji Okuse; Mark D Baker
Journal:  J Neurobiol       Date:  2004-10

Review 2.  Resurgence of sodium channel research.

Authors:  A L Goldin
Journal:  Annu Rev Physiol       Date:  2001       Impact factor: 19.318

3.  Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.

Authors:  Yejia Song; John C Shryock; Lin Wu; Luiz Belardinelli
Journal:  J Cardiovasc Pharmacol       Date:  2004-08       Impact factor: 3.105

4.  State-dependent trapping of flecainide in the cardiac sodium channel.

Authors:  Eugene Ramos; Michael E O'leary
Journal:  J Physiol       Date:  2004-07-22       Impact factor: 5.182

5.  Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.

Authors:  Gernot Schram; Liming Zhang; Katayoun Derakhchan; Joachim R Ehrlich; Luiz Belardinelli; Stanley Nattel
Journal:  Br J Pharmacol       Date:  2004-07-26       Impact factor: 8.739

6.  Tryptophan scanning of D1S6 and D4S6 C-termini in voltage-gated sodium channels.

Authors:  Sho-Ya Wang; Kaitlin Bonner; Corinna Russell; Ging Kuo Wang
Journal:  Biophys J       Date:  2003-08       Impact factor: 4.033

Review 7.  Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.

Authors:  Charles Antzelevitch; Luiz Belardinelli; Lin Wu; Heather Fraser; Andrew C Zygmunt; Alexander Burashnikov; José M Di Diego; Jeffrey M Fish; Jonathan M Cordeiro; Robert J Goodrow; Fabiana Scornik; Guillermo Perez
Journal:  J Cardiovasc Pharmacol Ther       Date:  2004-09       Impact factor: 2.457

8.  Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.

Authors:  Alexander Burashnikov; José M Di Diego; Andrew C Zygmunt; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circulation       Date:  2007-09-04       Impact factor: 29.690

9.  Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain.

Authors:  Mohammed A Nassar; L Caroline Stirling; Greta Forlani; Mark D Baker; Elizabeth A Matthews; Anthony H Dickenson; John N Wood
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-16       Impact factor: 11.205

10.  State-dependent block of wild-type and inactivation-deficient Na+ channels by flecainide.

Authors:  Ging Kuo Wang; Corinna Russell; Sho-Ya Wang
Journal:  J Gen Physiol       Date:  2003-08-11       Impact factor: 4.086

View more
  39 in total

1.  Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine.

Authors:  Serge Sicouri; Jonathan Blazek; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-03-09

2.  Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels.

Authors:  Hai Huang; Silvia G Priori; Carlo Napolitano; Michael E O'Leary; Mohamed Chahine
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-12       Impact factor: 4.733

3.  Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.

Authors:  Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  J Pharmacol Exp Ther       Date:  2011-10-17       Impact factor: 4.030

4.  Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: II. Insights from a mathematical model.

Authors:  Vladislav V Nesterenko; Andrew C Zygmunt; Sridharan Rajamani; Luiz Belardinelli; Charles Antzelevitch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-08-05       Impact factor: 4.733

5.  Pharmacology of the Nav1.1 domain IV voltage sensor reveals coupling between inactivation gating processes.

Authors:  Jeremiah D Osteen; Kevin Sampson; Vivek Iyer; David Julius; Frank Bosmans
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-12       Impact factor: 11.205

6.  Ranolazine Therapy Reduces Non-ST-Segment-Elevation Myocardial Infarction and Unstable Angina in Coronary Disease Patients with Angina.

Authors:  Gary L Murray; Joseph Colombo
Journal:  Int J Angiol       Date:  2016-04-28

7.  Ranolazine attenuates behavioral signs of neuropathic pain.

Authors:  Harry J Gould; Colleen Garrett; Renee R Donahue; Dennis Paul; Ivan Diamond; Bradley K Taylor
Journal:  Behav Pharmacol       Date:  2009-12       Impact factor: 2.293

8.  Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria.

Authors:  Serge Sicouri; Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12-01

9.  Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability.

Authors:  Mark Estacion; Stephen G Waxman; Sulayman D Dib-Hajj
Journal:  Mol Pain       Date:  2010-06-08       Impact factor: 3.395

10.  Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons.

Authors:  C H Peters; S Sokolov; S Rajamani; P C Ruben
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.